For nearly half of people diagnosed with lung cancer, immunotherapy can slow the disease but not stop it. Funded through a $4 million joint investment from the Canadian Cancer Society (CCS) and the Weston Family Foundation, a new clinical trial aims to change that.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Autologous Stem Cell Transplant in Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
A new survey study SC32S, collecting sociodemographic data from clinical trial participants, has now opened across Canada. This study will help researchers understand the feasibility of using a survey to gather information about trial participants’ backgrounds and everyday lives.
Phase II Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for New Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
Investigating Precision Medicine in the Adjuvant setting: a phase III Clinical Trial in Biliary tract cancer (SAFIR IMPACT BTC)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Radiotherapy (REVERT) in Patients with HNSCC
The next CCTG Clinical Research Associate (CRA) Lunch and Learn training session will be on Wednesday Jun 24th, 2025, at 12 pm ET, covering the top
A new national initiative as been funded by the Canadian Cancer Society, through their Breakthrough Team Grant competition. The Canadian Network for Psychedelic-Assisted Cancer Therapy (CAN-PACT), is bringing together researchers, clinicians, policymakers, and people living with advanced cancer to explore the potential of psychedelic-assisted therapy as a transformative approach to cancer care.
Primary Publication
CCTG will be holding the next CRA Lunch and Learn on Wednesday March 26th, 2025, at 12 pm ET. Session 4 will cover the topic of Introduction to RIPPLE: CCTG's rostering and participants list system
The Canadian Cancer Trials Group (CCTG) is currently seeking applications for a Patient Representative for the Gastro-Intestinal Disease Site Committee. CCTG is an inclusive organization dedicated to building a diverse network. This is a volunteer role for membership on the Gastro-Intestinal Disease Site Committee, the Gastro-Intestinal Disease Site Executive Committee, and the CCTG Patient Representative Committee.
The CCTG Annual Spring Meeting of Participants is fast approaching! We are excited to share important updates and additional information.
